Week in Review: Everest Announces Two In-Licensings with Total Value of $1 Billion

Deals and Financings   Shanghai Everest Medicines in-licensed a BTK inhibitor for renal diseases from Suzhou Sinovent and SinoMab Bio in a $561 million agreement; Everest also announced a $500 million deal for a mRNA COVID-19 vaccine and two other mRNA producs from Canada 's Providence Therapeutics; Cue Health, a  San Diego  company with China backers, filed for a $180 million US IPO to develop its home healthcare device, including a COVID-19 test; Haisco Pharma of Shannan in-licensed  China  rights to a novel osteoarthritis therapy from  San Diego 's Biosplice in a $140 million agreement; IASO, a  Nanjing  biopharma, completed a $108 million Series C round to advance its novel cell therapy and biologic products; Alebund Pharma, a  Shanghai  company focused on renal diseases, closed a $54.5 million Series B+ financing round; Florida 's Cytovia established a Shanghai JV with an initial $45 million to develop its off-the-shelf CAR products in  China ;  Trials and Approvals   Nanjing Legend Biotech was approved for a US Phase 1 trial of its autologous CD4 CAR-T lymphoma therapy; CStone Pharma of  Suzhou  will start  China  trials of its tri-specific immunotherapy, a next-gen anti-PD-1/PD-L1 that also targets 4-1BB and human serum albumin; Harbour BioMed was approved to start  China  trials of its next-gen CLTA-4/PD-1 candidate for hepatocellular and neuroendocrine carcinoma.  Stock Symbols: (HK 1952) (HK: 3681) (SHZ: 002653) (NSDQ: LEGN) (HK: 2616) (HK: 02142) Share this with colleagues: // //